Trastuzumab (herceptin) and HER2-positive breast cancer

被引：8
|
作者：
Murray, S
机构：
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 2006年 / 174卷 / 01期
关键词：
D O I：
10.1503/cmaj.051452
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：36 / 37
页数：2
相关论文
共 50 条
  • [21] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Young-A Heo
    Yahiya Y. Syed
    Targeted Oncology, 2019, 14 : 749 - 758
  • [22] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [23] The art of prescribing trastuzumab for HER2-positive breast cancer
    Outhoff, K.
    SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2011, 3 (01) : 16 - 26
  • [24] Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer
    Xiaoying Chen
    Cheryl Li
    Reginald Ewesuedo
    Donghua Yin
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 83 - 92
  • [25] Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer
    Chen, Xiaoying
    Li, Cheryl
    Ewesuedo, Reginald
    Yin, Donghua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 83 - 92
  • [26] Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
    Wilson, Florence R.
    Coombes, Megan E.
    Brezden-Masley, Christine
    Yurchenko, Mariya
    Wylie, Quinlan
    Douma, Reuben
    Varu, Abhishek
    Hutton, Brian
    Skidmore, Becky
    Cameron, Chris
    SYSTEMATIC REVIEWS, 2018, 7
  • [27] Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells
    Varshosaz, Jaleh
    Davoudi, Mohammad Ali
    Rasoul-Amini, Sara
    JOURNAL OF LIPOSOME RESEARCH, 2018, 28 (04) : 285 - 295
  • [28] Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
    Florence R. Wilson
    Megan E. Coombes
    Christine Brezden-Masley
    Mariya Yurchenko
    Quinlan Wylie
    Reuben Douma
    Abhishek Varu
    Brian Hutton
    Becky Skidmore
    Chris Cameron
    Systematic Reviews, 7
  • [29] Systematic review of cost-effectiveness-analysis studies of trastuzumab (Herceptin™) in treatment of HER2-positive breast cancer
    Le, Q. A.
    VALUE IN HEALTH, 2008, 11 (03) : A60 - A60
  • [30] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
12345